Open company graph database — free web & API
Login

Kringle Pharma Inc.

クリングルファーマ株式会社Kringle Pharma, Inc.Alias
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
17
Related companies
4
§01

Basic information

BASIC
Head office
4-3-51 Nakanoshima Qross, 10th Floor, Future Medical R&D Center, Nakanoshima, Kita-ku, Osaka, 530-0005, Japan
Chief executive
Kiyohiro Adachi
Capital
64,000,000
Employees (non-consolidated)
17 people
Employees (consolidated)
17 people
Start date
2001-12-21
End date
§02

Websites

1 DOMAINS
§03

Business

3
Research and development of HGF as a pharmaceuticalManufacturing of HGF as a pharmaceuticalSales of HGF as a pharmaceutical
§04

Related companies

4 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Kringle Pharma USA, Inc.
Group Subsidiary
Maruishi Pharmaceutical Co., Ltd.
Alliance
Toho Holdings Co., Ltd.
Alliance
Claris Biotherapeutics, Inc.
Alliance
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

31 EVENTS

Founded Kringle Pharma Inc. in Kita-ku, Osaka City.Sources

Established Clingul Pharma Co., Ltd. as a drug discovery bio‑venture originating from Osaka University and Keio University.Sources

Obtained development rights for HGF protein from the late Professor Toshio Nakamura (Professor Emeritus, Osaka University) and commenced development (development code: KP-100).Sources

Established a manufacturing method for large-scale production of HGF protein active ingredient (pharmaceutical grade).Sources

Completed a Phase Ib clinical trial of HGF protein in patients with renal failure in the United States.Sources

Completed a Phase I clinical trial of HGF protein in ALS patients in Japan.Sources

Completed a Phase I/II clinical trial (physician-led) of HGF protein in patients with vocal fold scarring in Japan.Sources

Completed a Phase I/II clinical trial of HGF protein in acute spinal cord injury patients in Japan.Sources

The Ministry of Health, Labour and Welfare designated HGF protein for acute spinal cord injury as a rare disease drug.Sources

Capital and business alliance with Toho Holdings Inc. to establish a wholesale distribution system for HGF drug targeting acute spinal cord injury.Sources

Signed a license and supply agreement with Clarus BioTherapeutics Inc. in the United States.Sources

Initiated a Phase III clinical trial of KP-100IT in acute spinal cord injury patients in Japan.Sources

Capital and business alliance with Maruishi Pharmaceutical Co., Ltd. to build a sales system for KP-100IT targeting acute spinal cord injury.Sources

Listed shares on the Tokyo Stock Exchange Mothers market (now Growth market).Sources

Signed a joint research agreement with Keio University School of Medicine to apply HGF therapy for spinal cord injury.Sources

Initiated a Phase I/II clinical trial targeting neurotrophic keratitis by Clarus BioTherapeutics Inc. in the United States.Sources

The international nonproprietary name for recombinant human HGF protein (KP-100) was designated as 'Oremepermin Alfa'.Sources

The international non‑proprietary name for recombinant human HGF protein (KP‑100) was decided as 'Oremepermin Alfa'.Sources

Registered a European patent for 'HGF formulation suitable for treating neurological disorders'.Sources

Co-filed a patent with Keio University School of Medicine on treatment for chronic spinal cord injury.Sources

Co-filed a patent with Keio University School of Medicine on combined HGF and iPS cell therapy for spinal cord injury.Sources

Initiated a Phase III trial of HGF protein in patients with vocal fold scarring in Japan.Sources

Started collaboration with Clarus Biotherapeutics in the U.S. to improve efficiency and scale of recombinant human HGF protein production.Sources

Completed the final observation day of the Phase III clinical trial targeting acute spinal cord injury.Sources

Released preliminary results of the Phase III clinical trial for acute spinal cord injury.Sources

The Japanese generic name for HGF was decided as 'Oremepelin Alpha'.Sources

The Japanese generic name for HGF was decided as 'Oremepelin Alpha'.Sources

Opened the Nakanoshima Qross office.Sources

Recombinant human HGF protein targeting acute spinal cord injury obtained orphan drug designation in the U.S.Sources

Developed a general business action plan.Sources

Establishment of U.S. subsidiary (Kringle Pharma USA, Inc.)Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information7120901027189
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
クリングルファーマ株式会社
Trade name (kana)
クリングルファーマ
Name in English
Corporation type
301
Address
〒530-0005 大阪府大阪市北区中之島4丁目3番51号
Postal code
5300005
Prefecture code
27
City code
127
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2026-01-09
Change date
2026-01-07
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
4344786
METI gBizINFO7120901027189
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
7120901027189
Trade name
クリングルファーマ株式会社
Trade name (kana)
クリングルファーマ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
大阪府大阪市北区中之島4丁目3番51号
Postal code
5300005
Prefecture
大阪府
Prefecture code
27
City or district
大阪市北区
City code
127
Street address
中之島4丁目3番51号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
代表取締役社長  安達 喜一
Capital
64176000
Employees
17
Employees (male)
Employees (female)
Business summary
HGFを医薬品とするための研究開発、製造、販売
Website URL
Year founded
Business category
E:製造業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2026-01-09
Key information
7120901027189
§09

Sources & updates

SOURCES
↑